Literature DB >> 25854649

Acute management of brain arteriovenous malformations.

Andreas Hartmann1, J P Mohr.   

Abstract

OPINION STATEMENT: Major reasons to treat brain arteriovenous malformations (AVMs) are to reduce the risk of brain hemorrhage, control intractable seizure, and in some cases alleviate neurologic deficits. Once an AVM has hemorrhaged, the risk of further hemorrhage is increased and it should be treated. The treatment plan ideally is based on interdisciplinary discussion between neurosurgery, endovascular neuroradiology, and radiotherapy, moderated by neurology in an experienced center. Complete removal or obliteration of the malformation should be the goal, as partial treatment only exposes the patient to treatment risks with a residual hemorrhage risk. If an AVM is surgically accessible with acceptable treatment risk, neurosurgical removal leads to the fastest and most complete reduction of hemorrhage risk. Radiotherapy is best used in small AVMs with contraindications to surgery. Endovascular embolization can be used as an adjunct for both to facilitate removal or obliteration or to reduce risks from associated aneurysms or high-flow fistulae, and may in some cases lead to complete occlusion. Unbled AVMs require a thorough assessment of projected hemorrhage risk versus treatment risks, as the natural course is influenced by clinical and morphological factors. Given recent scientific evidence, those with low projected hemorrhage risks should be managed conservatively, receiving the best medical treatment of accompanying symptoms, and careful clinical and follow-up imaging monitoring. Thorough and objective counselling of the patients about pros and contras of therapy, detailed explanation of recommendations, and possible reevaluation of treatment decisions at later timepoints are recommended.

Entities:  

Year:  2015        PMID: 25854649     DOI: 10.1007/s11940-015-0346-5

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  116 in total

1.  Seizure predictors and control after microsurgical resection of supratentorial arteriovenous malformations in 440 patients.

Authors:  Dario J Englot; William L Young; Seunggu J Han; Charles E McCulloch; Edward F Chang; Michael T Lawton
Journal:  Neurosurgery       Date:  2012-09       Impact factor: 4.654

2.  Management of brain arteriovenous malformations.

Authors:  Michael T Lawton; Adib A Abla
Journal:  Lancet       Date:  2014-05-10       Impact factor: 79.321

3.  Management of brain arteriovenous malformations--authors' reply.

Authors:  Christian Stapf; Michael K Parides; Alan J Moskowitz; J P Mohr
Journal:  Lancet       Date:  2014-05-10       Impact factor: 79.321

Review 4.  [Postoperative morbidity and mortality after microsurgical exclusion of cerebral arteriovenous malformations. Current data and analysis of recent literature].

Authors:  J P Castel; G Kantor
Journal:  Neurochirurgie       Date:  2001-05       Impact factor: 1.553

5.  Embolization before radiosurgery reduces the obliteration rate of arteriovenous malformations.

Authors:  Yuri M Andrade-Souza; Meera Ramani; Daryl Scora; May N Tsao; Karel terBrugge; Michael L Schwartz
Journal:  Neurosurgery       Date:  2007-03       Impact factor: 4.654

6.  Intention-to-treat analysis of Spetzler-Martin grades IV and V arteriovenous malformations: natural history and treatment paradigm.

Authors:  Patrick P Han; Francisco A Ponce; Robert F Spetzler
Journal:  J Neurosurg       Date:  2003-01       Impact factor: 5.115

7.  Frequency of intracranial hemorrhage as a presenting symptom and subtype analysis: a population-based study of intracranial vascular malformations in Olmsted Country, Minnesota.

Authors:  R D Brown; D O Wiebers; J C Torner; W M O'Fallon
Journal:  J Neurosurg       Date:  1996-07       Impact factor: 5.115

8.  Endovascular treatment of intracranial microarteriovenous malformations.

Authors:  Alexander Andreou; Ioannis Ioannidis; Shivendra Lalloo; Nasis Nickolaos; James V Byrne
Journal:  J Neurosurg       Date:  2008-12       Impact factor: 5.115

9.  Clinical and morphological determinants of focal neurological deficits in patients with unruptured brain arteriovenous malformation.

Authors:  J H Choi; H Mast; A Hartmann; R S Marshall; J Pile-Spellman; J P Mohr; C Stapf
Journal:  J Neurol Sci       Date:  2009-09-03       Impact factor: 3.181

10.  Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial.

Authors:  J P Mohr; Michael K Parides; Christian Stapf; Ellen Moquete; Claudia S Moy; Jessica R Overbey; Rustam Al-Shahi Salman; Eric Vicaut; William L Young; Emmanuel Houdart; Charlotte Cordonnier; Marco A Stefani; Andreas Hartmann; Rüdiger von Kummer; Alessandra Biondi; Joachim Berkefeld; Catharina J M Klijn; Kirsty Harkness; Richard Libman; Xavier Barreau; Alan J Moskowitz
Journal:  Lancet       Date:  2013-11-20       Impact factor: 79.321

View more
  1 in total

1.  Radiomics Analysis for Predicting Epilepsy in Patients With Unruptured Brain Arteriovenous Malformations.

Authors:  Shaozhi Zhao; Qi Zhao; Yuming Jiao; Hao Li; Jiancong Weng; Ran Huo; Jie Wang; Hongyuan Xu; Junze Zhang; Yan Li; Zhenzhou Wu; Shuo Wang; Yong Cao; Jizong Zhao
Journal:  Front Neurol       Date:  2021-12-15       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.